Circulating tumor cells: Detection, molecular profiling and future prospects

Expert Review of Proteomics

Volumn 4, Issue 6, 2007, Pages 741-756

  Jacob, Karine ^b   Sollier, Caroline ^b   Jabado, Nada ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Cancer therapy; Circulating tumor cell; Cytometry; Epithelial mesenchymal transition; Invasion; Metastasis; Microarray; PCR; Prognostic marker; SNP

Indexed keywords

PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN A;

ADENOCARCINOMA; BREAST; CANCER RESEARCH; COLON; CYTOLOGY; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; NONHUMAN; ONCOGENE RAS; PANCREAS; POLYMERASE CHAIN REACTION; PROSTATE; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; TECHNOLOGY; TUMOR CELL;

AUTOMATION; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MESODERM; MODELS, BIOLOGICAL; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEINS; PROTEOME; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 37149040822     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.6.741     Document Type: Review

References (122)

1. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 19(3-4), 193-383 (2000).
2. Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother. Pharmacol. 43(Suppl.), S3-S10 (1999).
3. Coman DR, deLong RP, MccUtcheon M. Studies on the mechanisms of metastasis; the distribution of tumors in various organs in relation to the distribution of arterial emboli. Cancer Res. 11(8), 648-651 (1951).
4. Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol. Med. 12(3), 130-139 (2006).
5. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7(5), 704-710 (1995).
6. Fidler IJ. Critical determinants of metastasis. Semin. Cancer Biol. 12(2), 89-96 (2002).
7. Okegawa T, Noda H, Kato M et al. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 44(3), 210-218 (2000).
8. Abbruzzese JL, Abbruzzese MC, Hess KR et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J. Clin. Oncol. 12(6), 1272-1280 (1994).
9. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J. 6(Suppl. 2), S134-S141 (2000).
10. Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg. Oncol. Clin. N. Am. 10(2), 257-269, vii-viiii (2001).
11. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3(6), 453-458 (2003).
12. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 3(1), 53-57 (2002).
13. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889).
14. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118(3), 277-279 (2004).
15. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6(1), 3-18 (1995).
16. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824), 50-56 (2001).
17. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2(3), 161-174 (2002).
18. Janda E, Lehmann K, Killisch I et al. Ras and TGF-β cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol. 156(2), 299-313 (2002).
19. Leptin M, Grunewald B. Cell shape changes during gastrulation in Drosophila. Development 110(1), 73-84 (1990).
20. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol.15(6), 740-746 (2003).
21. Berx G, Cleton-Jansen AM, Nollet F et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 14(24), 6107-6115 (1995).
22. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62(6), 1613-1618 (2002).
23. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34(3), 255-268 (2002).
24. Yoshiura K, Kanai Y, Ochiai A et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl Acad. Sci. USA 92(16), 7416-7419 (1995).
25. Brabletz T, Jung A, Hermann K et al. Nuclear overexpression of the oncoprotein ?-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract. 194(10), 701-704 (1998).
26. Batlle E, Sancho E, Franci C et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2(2), 84-89 (2000).
27. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 12(6), 488-496 (2005).
28. Rosivatz E, Becker I, Specht K et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol. 161(5), 1881-1891 (2002).
29. Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res. 66(9), 4549-4552 (2006).
30. Soo K, O'Rourke MP, Khoo PL et al. Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo. Dev. Biol. 247(2), 251-270 (2002).
31. Hotz B, Arndt M, Dullat S et al. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin. Cancer Res. 13(16), 4769-4776 (2007).
32. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 66(17), 8319-8326 (2006).
33. Meng S, Tripathy D, Frenkel EP et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10(24), 8152-8162 (2004).
34. Naumov GN, MacDonald IC, Chambers AF, Groom AC. Solitary cancer cells as a possible source of tumour dormancy? Semin. Cancer Biol. 11(4), 271-276 (2001).
35. Al-Mehdi AB, Tozawa K, Fisher AB et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med. 6(1), 100-102 (2000).
36. Klement H, St Croix B, Milsom C et al. Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am. J. Pathol. 171(4), 1342-1351 (2007).
37. Nanda A, Karim B, Peng Z et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc. Natl Acad. Sci. USA 103(9), 3351-3356 (2006).
38. Seaman S, Stevens J, Yang MY et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11(6), 539-554 (2007).
39. St Croix B, Sheehan C, Rak JW et al. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol. 142(2), 557-571 (1998).
40. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40(7), 2281-2287 (1980).
41. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 66(23), 11089-11093 (2006).
42. Tarin D, Price JE, Kettlewell MG et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 44(8), 3584-3592 (1984).
43. Tarin D, Vass AC, Kettlewell MG, Price JE. Absence of metastatic sequelae during long-term treatment of malignant ascites by peritoneo-venous shunting. A clinico-pathological report. Invasion Metastasis 4(1), 1-12 (1984).
44. Scadden DT. The stem-cell niche as an entity of action. Nature 441(7097), 1075-1079 (2006).
45. Ridell B, Landys K. Incidence and histopathology of metastases of mammary carcinoma in biopsies from the posterior iliac crest. Cancer 44(5), 1782-1788 (1979).
46. Mansi JL, Gogas H, Bliss JM et al. Outcome of primary-breast- cancer patients with micrometastases: a long-term follow-up study. Lancet 354(9174), 197-202 (1999).
47. Redding WH, Coombes RC, Monaghan P et al. Detection of micrometastases in patients with primary breast cancer. Lancet 2(8362), 1271-1274 (1983).
48. Pantel K, Alix-Panabieres C. The clinical significance of circulating tumor cells. Nat. Clin. Pract. Oncol. 4(2), 62-63 (2007).
49. Morgan TM, Lange PH, Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells. Front. Biosci. 12, 3000-3009 (2007).
50. Boyum A, Lovhaug D, Tresland L, Nordlie EM. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol. 34(6), 697-712 (1991).
51. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 253(2), 180-204 (2007).
52. Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am. J. Pathol. 156(1), 57-63 (2000).
53. Ellis WJ, Pfitzenmaier J, Colli J et al. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 61(2), 277-281 (2003).
54. Witzig TE, Bossy B, Kimlinger T et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin. Cancer Res. 8(5), 1085-1091 (2002).
55. Loberg RD, Fridman Y, Pienta BA et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia 6(4), 302-309 (2004).
56. Moreno JG, Miller MC, Gross S et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65(4), 713-718 (2005).
57. Goeminne JC, Guillaume T. Detection of circulating tumor by reverse transcriptase polymerase chain reaction. J. Clin. Oncol. 18(17), 3196-3197 (2000).
58. Schoenfeld A, Luqmani Y, Smith D et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 54(11), 2986-2990 (1994).
59. Silva JM, Rodriguez R, Garcia JM et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 50(4), 530-534 (2002).
60. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin. Cancer Res. 11(22), 8006-8014 (2005).
61. Fehm T, Braun S, Muller V et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107(5), 885-892 (2006).
62. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6(11), 835-845 (2006).
63. Gerhard M, Juhl H, Kalthoff H et al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J. Clin. Oncol. 12(4), 725-729 (1994).
64. Ghossein RA, Scher HI, Gerald WL et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J. Clin. Oncol. 13(5), 1195-1200 (1995).
65. Kaplan JC, Kahn A, Chelly J. Illegitimate transcription: its use in the study of inherited disease. Hum. Mutat. 1(5), 357-360 (1992).
66. Johnson PW, Burchill SA, Selby PJ. The molecular detection of circulating tumour cells. Br. J. Cancer 72(2), 268-276 (1995).
67. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin. Cancer Res. 5(8), 1950-1960 (1999).
68. Ghossein RA, Carusone L, Bhattacharya S. Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. Diagn. Mol. Pathol. 8(4), 165-175 (1999).
69. Ghossein RA, Osman I, Bhattacharya S et al. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn. Mol. Pathol. 8(2), 59-65 (1999).
70. Smerage JB, Hayes DF. The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br. J. Cancer 94(1), 8-12 (2006).
71. Hu XC, Wang Y, Shi DR, Loo TY, Chow LW. Immunomagnetic tumor cell enrichment is promising in detecting circulating breast cancer cells. Oncology 64(2), 160-165 (2003).
72. Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338(8777), 1227-1229 (1991).
73. Ghossein RA, Coit D, Brennan M et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin. Cancer Res. 4(2), 419-428 (1998).
74. Mocellin S, Del Fiore P, Guarnieri L et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int. J. Cancer 111(5), 741-745 (2004).
75. Osella-Abate S, Savoia P, Quaglino P et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br. J. Cancer 89(8), 1457-1462 (2003).
76. Voit C, Kron M, Rademaker J et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J. Clin. Oncol. 23(6), 1218-1227 (2005).
77. Wascher RA, Morton DL, Kuo C et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J. Clin. Oncol. 21(13), 2558-2563 (2003).
78. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
79. Iakovlev VV, Goswami RS, Vecchiarelli J, Arneson NC, Done SJ. Quantitative detection of circulating epithelial cells by Q-RT-PCR. Breast Cancer Res. Treat. 107(1), 145-154 (2007).
80. Schmidt-Kittler O, Ragg T, Daskalakis A et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100(13), 7737-7742 (2003).
81. Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12(14 Pt 1), 4218-4224 (2006).
82. Wulfing P, Borchard J, Buerger H et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 12(6), 1715-1720 (2006).
83. Ulmer A, Schmidt-Kittler O, Fischer J et al. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin. Cancer Res. 10(2), 531-537 (2004).
84. Bozionellou V, Mavroudis D, Perraki M et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 10(24), 8185-8194 (2004).
85. Shariat SF, Kattan MW, Song W et al. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 63(18), 5874-5878 (2003).
86. Mikulowska-Mennis A, Taylor TB, Vishnu P et al. High-quality RNA from cells isolated by laser capture microdissection. Biotechniques 33(1), 176-179 (2002).
87. Faury D, Nantel A, Dunn SE et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J. Clin. Oncol. 25(10), 1196-1208 (2007).
88. Gebauer G, Krones-Herzig A, Glinskii AB, Glinsky GV. Identification of genes associated with tumor progression using microarrays. Anticancer Res. 25(3A), 1477-1482 (2005).
89. Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 4(9), 1171-1175 (2005).
90. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115(6), 1503-1521 (2005).
91. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33(1), 49-54 (2003).
92. Smirnov DA, Foulk BW, Doyle GV et al. Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res. 66(6), 2918-2922 (2006).
93. Klein CA, Blankenstein TJ, Schmidt-Kittler O et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334), 683-689 (2002).
94. Schwarzenbach H, Muller V, Stahmann N, Pantel K. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann. NY Acad. Sci. 1022, 25-32 (2004).
95. Muller V, Pantel K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res. 6(6), 258-261 (2004).
96. Kraus J, Pantel K, Pinkel D, Albertson DG, Speicher MR. High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer 36(2), 159-166 (2003).
97. Steemers FJ, Chang W, Lee G et al. Whole-genome genotyping with the single-base extension assay. Nat. Methods 3(1), 31-33 (2006).
98. Gunderson KL, Kuhn KM, Steemers FJ et al. Whole-genome genotyping of haplotype tag single nucleotide polymorphisms. Pharmacogenomics 7(4), 641-648 (2006).
99. Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet. 37(5), 549-554 (2005).
100. Fan JB, Chee MS, Gunderson KL. Highly parallel genomic assays. Nat. Rev. Genet. 7(8), 632-644 (2006).
101. Alix-Panabieres C, Brouillet JP, Fabbro M et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J. Immunol. Methods 299(1-2), 177-188 (2005).
102. Alix-Panabieres C, Vendrell JP, Pelle O et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin. Chem. 53(3), 537-539 (2007).
103. Koch M, Kienle P, Hinz U et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann. Surg. 241(2), 199-205 (2005).
104. Bessa X, Pinol V, Castellvi-Bel S et al. Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure. Ann. Surg. 237(3), 368-375 (2003).
105. Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg. 232(1), 58-65 (2000).
106. Giatromanolaki A, Koukourakis MI, Kakolyris S et al. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int. J. Cancer 108(4), 620-627 (2004).
107. Stathopoulou A, Vlachonikolis I, Mavroudis D et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20(16), 3404-3412 (2002).
108. Jotsuka T, Okumura Y, Nakano S et al. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery 135(4), 419-426 (2004).
109. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van't Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br. J. Cancer 88(7), 1091-1094 (2003).
110. Pierga JY, Bonneton C, Vincent-Salomon A et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 10(4), 1392-1400 (2004).
111. de la Taille A, Olsson CA, Buttyan R et al. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int. J. Cancer 84(4), 360-364 (1999).
112. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J. Clin. Oncol. 21(3), 490-495 (2003).
113. Thomas J, Gupta M, Grasso Y et al. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J. Clin. Oncol. 20(15), 3213-3218 (2002).
114. Domingo-Domenech J, Molina R, Castel T et al. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon - comparison with tyrosinase rt-PCR. Oncology 68(4-6), 341-349 (2005).
115. Gogas H, Kefala G, Bafaloukos D et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer 87(2), 181-186 (2002).
116. Proebstle TM, Jiang W, Hogel J et al. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br. J. Cancer 82(1), 118-123 (2000).
117. Reynolds SR, Albrecht J, Shapiro RL et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 9(4), 1497-1502 (2003).
118. Hoon DS, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60(8), 2253-2257 (2000).
119. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J. Clin. Oncol. 17(8), 2562-2571 (1999).
120. Schmidt H, Sorensen BS, Fode K, Nexo E, von der Maase H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res. 15(5), 409-416 (2005).
121. Palmieri G, Ascierto PA, Perrone F et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol. 21(5), 767-773 (2003).
122. Human Genome Project www.hapmap.org